Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

Share Price is delayed by 15 minutes
Get Live Data
6.40    0.00 (0.00%)
Bid:
6.30
Ask:
6.50
Spread: 0.20 (3.175%)
Market Cap: £6.61m
OPTI Live PriceLast checked at - London Stock Exchange

Intraday OptiBiotix Health Share Chart

Half Yearly Results

18 Jul 2014 07:00

RNS Number : 6690M
Ducat Ventures PLC
18 July 2014
 



Ducat Ventures Plc ("Company")

 

Half Yearly Report

 

The Board of Ducat presents the unaudited historical financial information of the Company for the 6 months to 31 May 2014. 

 

Consolidated Statement of Comprehensive Income

For the six months ended 31 May 2014

 

 

 

 

Six months

 to 31 May

2014

Six months

 to 31 May

2013

 

 

 

(Unaudited)

(Unaudited)

Continuing operations

 

 

£

£

 

 

 

 

 

Revenue

 

 

-

-

Cost of Sales

 

 

-

-

 

 

 

───────

───────

 

 

 

 

 

Gross Loss

 

 

-

-

 

 

 

 

 

Administrative expenses

 

 

(57,643)

(166,453)

 

 

 

───────

───────

Operating Loss

 

 

(57,643)

(166,453)

 

 

 

 

 

Non Operating Items

 

 

 

 

Impairment of investments

 

 

-

(500,000)

Impairment of intercompany loans

 

 

-

(1,384,068)

Surplus arising on settlements with trade creditors

 

 

 

-

 

-

 

 

 

───────

───────

 

 

 

(57,643)

(2,050,521)

 

 

 

 

 

Finance Costs

 

 

-

-

 

 

 

───────

───────

Loss Before Tax

 

 

(57,643)

(2,050,521)

 

 

 

 

 

Taxation

 

 

-

-

 

 

 

───────

───────

Total comprehensive income for the period

 

 

 

(57,643)

 

(2,050,521)

 

 

 

═══════

═══════

 

 

 

 

 

Loss per share

 

 

0.006p

2.29p

 

 

 

═══════

═══════

 

 

 

 

 

 

 

 

Consolidated Balance Sheet

For the six months ended 31 May 2014

 

 

 

 

Six months

 to 31 May

2014

Six months

to 31 May

2013

 

 

 

(Unaudited)

(Unaudited)

ASSETS

 

 

£

£

 

 

 

 

 

 

 

 

 

 

CURRENT ASSETS

 

 

 

 

Trade and other receivables

 

 

10,034

49,077

Cash and cash equivalents

 

 

105,221

4,945

 

 

 

───────

───────

 

 

 

115,255

54,022

 

 

 

───────

───────

 

 

 

 

 

Total Assets

 

 

115,255

54,022

 

 

 

═══════

═══════

 

 

 

 

 

 

 

 

 

 

EQUITY

 

 

 

 

Shareholders' Equity

 

 

 

 

Called up share capital

 

 

5,742,586

5,636,083

Share premium

 

 

1,355,502

1,086,875

Share based payment reserve

 

 

27,200

27,200

Retained earnings

 

 

(7,013,950)

(6,830,754)

 

 

 

───────

───────

Total Equity

 

 

111,338

(80,596)

 

 

 

───────

───────

 

 

 

 

 

LIABILITIES

 

 

 

 

CURRENT LIABILITIES

 

 

 

 

 

 

 

 

 

Trade and other payables

 

 

3,917

134,618

 

 

 

───────

───────

 

 

 

3,917

134,618

 

 

 

───────

───────

Total Equity and Liabilities

 

 

115,255

54,022

 

 

 

══════

═══════

 

 

 

Consolidated statement of changes in equity

For the six months ended May 2014

 

 

 

 

Called up

Share

Capital

 

 

Share

Premium

Share-

Based

Payment

Reserve

 

 

Retained

Earnings

 

 

Total

Equity

 

£

£

£

£

£

 

 

 

 

 

 

Balance at 1 August 2012

5,574,070

838,822

27,200

(4,780,233)

1,659,859

 

 

 

 

 

 

Loss for period

-

-

-

(2,050,521)

(2,050,521)

 

 

 

 

 

 

Issue of shares

62,013

248,053

-

-

310,066

 

───────

──────

──────

───────

───────

Balance at 31 May 2013

5,636,083

1,086,875

27,200

(6,830,754)

(80,596)

 

 

 

 

 

 

Loss for the period

-

-

-

(125,553)

(125,553)

 

 

 

 

 

 

Issue of shares

86,165

215,936

-

-

302,101

 

───────

──────

──────

───────

───────

Balance at 30 November 2013

5,722,248

1,302,811

27,200

(6,956,307)

95,952

 

 

 

 

 

 

Loss for the period

-

-

-

(57,643)

(57,643)

 

 

 

 

 

 

Issue of ordinary shares at £0.0004 per shares less cost

 

20,338

 

52,691

-

 

 

-

 

73,029

 

───────

──────

──────

───────

───────

Balance at 31 May 2014

5,742,586

1,355,502

27,200

(7,013,950)

113,338

 

══════

══════

══════

══════

═══════

 

 

Consolidated Statement of Cash Flows

As at 31 May 2014

 

 

 

 

 

Six months

 to 31 May

2014

Six months 

to 31 May

2013

 

 

(Unaudited)

(Unaudited)

 

 

£

£

 

 

 

 

Cash flows from operating activities

 

 

 

Loss before tax

 

(57,643)

(166,453)

(Increase)/decrease in trade and other

 receivables

 

 

291,233

 

(81,262)

Increase)/decrease in trade and other

payables

 

 

(201,548)

 

(57,416)

 

 

───────

───────

Net cash from operating activities

 

32,042

(305,131)

 

 

───────

───────

 

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

Issue of equity net of costs

 

73,029

310,067

Finance interest paid

 

-

-

 

 

───────

───────

Net cash from financing activities

 

73,029

310,067

 

 

───────

───────

 

 

 

 

Increase/(decrease) in cash and cash

equivalents

 

 

105,071

 

4,936

 

 

 

 

Cash and cash equivalents at the beginning of period

 

 

150

 

9

 

 

───────

───────

Cash and cash equivalents at the end of period

 

 

105,221

 

4,945

 

 

══════

═══════

 

 

 

 

 

Enquiries:

 

For further information, please contact:

Ducat Ventures plc

Nicholas Nelson

07921 522 920

Cairn Financial Advisers LLP

Liam Murray / Avi Robinson

020 7148 7900

Peterhouse Corporate Finance Ltd

Lucy Williams/ Duncan Vasey

020 7469 0936

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR FMGMNVNFGDZM
Date   Source Headline
13th Sep 20177:00 amRNSStrategic partnership with Bened Biomedical
11th Sep 201712:00 pmRNSHolding(s) in Company
7th Sep 20177:00 amRNSInvited to present at Expoquimia in Barcelona
6th Sep 20179:30 amRNSInvestor evening
5th Sep 20177:00 amRNSManufacturing Agreement with Tata Chemicals
1st Sep 20172:41 pmRNSExercise of Options and Issue of Equity
30th Aug 20177:00 amRNSHalf-year Report
24th Aug 20177:00 amRNSUS product launch of LPLDL® at trade show
22nd Aug 20177:00 amRNSGlobal manufacturing & supply agreement with Sacco
31st Jul 20174:27 pmRNSTotal Voting Rights
26th Jul 20177:00 amRNSMarket launch for LPLDL® capsules in Germany
17th Jul 20177:00 amRNSSupply agreement with Pharmabiota Ltd
11th Jul 20177:00 amRNSSweetBiotix® development: Results of taste study
6th Jul 20177:00 amRNSGrant of Options
15th Jun 201712:30 pmRNSResult of AGM
15th Jun 20177:00 amRNSSupply agreement with HLH Biopharma GmbH
31st May 20177:00 amRNSHolding(s) in Company
16th May 20177:00 amRNSSuccessful launch of LPLDL and SlimBiome products
9th May 20177:00 amRNSLPLDL® Non-Exclusive European License Agreement
3rd May 20177:00 amRNSPresentation of abstract at conference
25th Apr 20178:50 amRNSFirst German sales
25th Apr 20177:00 amRNSFinal Results
4th Apr 20177:00 amRNSNotice of Results
29th Mar 201710:47 amRNSUK Investor Show attendance
24th Mar 20175:35 pmRNSHolding(s) in Company
21st Mar 201712:00 pmRNSIntention to float SkinBiotherapeutics
15th Mar 20177:00 amRNSConfirmation of Director appointments to the Board
8th Mar 20177:00 amRNSEuropean agreement with Sacco Srl
1st Mar 20177:00 amRNSLaunch of products at Vitafoods 2017
8th Feb 20179:30 amRNSExercise of Warrants and Issue of Equity
26th Jan 20172:06 pmRNSResult of General Meeting
24th Jan 20177:00 amRNSPresentation of research data
18th Jan 20177:00 amRNSAppointment of Sales and Marketing Director
17th Jan 20174:50 pmRNSHolding(s) in Company
13th Jan 20173:44 pmRNSExercise of Option and Issue of Equity
12th Jan 20177:00 amRNSPresentation of research data at ProBiota 2017
11th Jan 201710:04 amRNSExercise of Warrants and Issue of Equity
5th Jan 20177:00 amRNSAppointment of Commercial Director
3rd Jan 20177:00 amRNSIncreased investment in THWLC
23rd Dec 20167:00 amRNSNotice of General Meeting of Warrant Holders
13th Dec 20167:00 amRNSJoint Product Agreement with multinational
1st Dec 20167:00 amRNSExercise of Warrants and Issue of Equity
29th Nov 20167:00 amRNSScientific and Commercial Update
3rd Nov 20167:00 amRNSPresentation of data at European Microbiome Summit
26th Oct 20167:00 amRNSScientific and commerical update
20th Oct 20167:00 amRNSIncreased investment in SkinBiotix Ltd
5th Oct 20167:00 amRNSAppointment of a Chairman for SkinBiotix
28th Sep 20167:00 amRNSChange of Adviser
23rd Sep 20168:29 amRNSExercise of Warrants and Issue of Equity
14th Sep 20164:38 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.